Optimizing ATR Inhibition and Cisplatin Synergy in Ewing Sarcoma.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 38861280.
- Also identified by DOI 10.1158/1078-0432.CCR-24-1047.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
EWSR1::FLI1-mediated dysregulation of cellular machinery opens up potential new avenues for Ewing sarcoma treatment. A recent study demonstrates that pharmacologic ATR kinase inhibition dramatically synergizes with low-dose cisplatin through EWSR1::FLI1-dependent rewiring of transcription, DNA repair, and translation machinery, which could maximize the therapeutic window of the combinatory therapy. See related article by Jess et al., p. 3533.
Medical subject headings
- Sarcoma, Ewing
- Cisplatin
- Ataxia Telangiectasia Mutated Proteins
- Drug Synergism